- Previous Close
29.90 - Open
32.25 - Bid 28.77 x 100
- Ask 29.26 x 100
- Day's Range
28.27 - 32.27 - 52 Week Range
6.58 - 33.77 - Volume
168,296 - Avg. Volume
191,064 - Market Cap (intraday)
860.089M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.93 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.10
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
dianthustx.comRecent News: DNTH
View More
Performance Overview: DNTH
Trailing total returns as of 11/8/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DNTH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DNTH
View MoreValuation Measures
Market Cap
860.09M
Enterprise Value
499.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
207.13
Price/Book (mrq)
2.40
Enterprise Value/Revenue
121.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.95%
Return on Equity (ttm)
-25.99%
Revenue (ttm)
5.37M
Net Income Avi to Common (ttm)
-67.09M
Diluted EPS (ttm)
-1.93
Balance Sheet and Cash Flow
Total Cash (mrq)
281.12M
Total Debt/Equity (mrq)
0.09%
Levered Free Cash Flow (ttm)
-43.81M
Research Analysis: DNTH
View MoreCompany Insights: DNTH
DNTH does not have Company Insights